Karen Ferrante, M.d.

Biography

Dr. Ferrante, a hematologist-oncologist, was appointed to MacroGenics’ Board of Directors in January 2017. She most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 20 years of oncology drug development experience to the Board. Prior to Tokai, Dr. Ferrante held several senior level positions at Millennium Pharmaceuticals and parent company Takeda Pharmaceuticals. Dr. Ferrante has also previously held positions of increasing responsibility at multiple pharmaceutical companies. She currently serves as a member of the boards of Progenics Pharmaceuticals and the New England Women in Science Executives Club. The Board believes that Dr. Ferrante’s medical training and 20 years of experience in oncology drug development qualify her to serve as a member of our Board. 

Research Interest

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our Dual-Affinity Re-Targeting, or DART®, and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. Our product candidates and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe